• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Breast Cancer Screening using MRI vs Mammography – How Do They Compare?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Mammography is the only test with evidence demonstrating breast cancer mortality reduction
  • MRI is recommended for women at high risk for breast cancer (for example, those with BRCA mutations or others with >20% lifetime risk)
  • Current guidelines recommend annual mammography for women with treated breast cancer and restricts the use of MRI screening to those at high risk
  • Buist et al. (JAMA Internal Medicine 2018) measured the biopsy rates and yield in the 90 days following screening (mammography vs MRI) in women with a personal history of breast cancer and based on breast cancer risk in women without personal history

METHODS:

  • Observational cohort study
    • Data from 6 Breast Cancer Surveillance Consortium (BCSC) registries
  • Participants
    • Women with ≥ 1 screening digital mammogram or screening breast MRI from 2003 to 2013
  • Women received either
    • Mammogram alone
    • MRI with or without mammogram within 30 days
  • Primary outcomes (within 90 days of screening episodes)
    • Biopsy intensity (most invasive procedure type)
    • Biopsy yield (most invasive finding)
  • Outcomes were stratified by
    • Personal history of breast cancer
    • BCSC 5-year breast cancer risk among women without personal history of breast cancer

RESULTS:

  • 812,164 women undergoing screening were included with a total of 2,048,994 imaging episodes
    • Women with personal history received 101,103 mammograms and 3,763 MRI screens
    • Women without personal history received 1,939,455 mammograms and 4673 MRI screens
  • In women with personal history, age-adjusted core and surgical biopsy rates (per 1000 episodes) doubled in MRI group (57.1; 95% CI, 50.3-65.1) vs mammography (23.6; 95% CI, 22.4-24.8)
  • In women without personal history, age adjusted core and surgical biopsy rates (per 1000 episodes) were 5 times higher following MRI (84.7; 95% CI, 75.9-94.9) vs mammography (14.9; 95% CI, 14.7-15.0)
  • In women with personal history, ductal carcinoma in situ and invasive biopsy yield (per 1000 episodes) were higher following mammography (404.6; 95% CI, 381.2-428.8) compared with MRI (267.6; 95% CI, 208.0-337.8)
  • Women without a personal history showed a similar but nonsignificant trend
  • High-risk benign lesions were more commonly identified following MRI regardless of personal history
  • Higher biopsy rates and lower cancer yield following MRI were not explained by increasing age or higher 5-year breast cancer risk

CONCLUSION:

  • Higher biopsy rates were expected with MRI because of its higher sensitivity and lower specificity compared with mammography
    • Unlike positive mammography which is usually followed by further targeted mammography or ultrasound, positive screening MRI results are usually resolved with short-interval follow-up MRI or biopsy
  • Women with and without personal history had higher biopsy rates and lower cancer yield findings after undergoing a screening MRI experience
  • Authors point out that this is study looked at 90 day rates, while traditional screening performance takes in to account examination interpretation within 12 months follow-up for cancer outcomes
  • In addition, the authors state that “further work is needed to identify women who will benefit from screening MRI to ensure an acceptable benefit-to-harm ratio.”

Learn More – Primary Sources:

Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Has Breast Density Legislation Had Any Impact on Breast Cancer Diagnosis? 
How Effective Is Mammography in Reducing the Number of Advanced Breast Cancer Diagnoses?
Mammography Guidelines for Average-Risk Women
Atypical Hyperplasia of the Breast: Follow up and Management

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site